Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression in Adolescence
Phase Not Applicable
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Trier Social Stress Test (TSST) — In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.

Primary Outcomes

  • Children's Depressing Rating Scale-Revised (baseline and 12-week follow-up)
  • Reynolds Adolescent Depression Scale-2 (RADS-2) (baseline and 12-week follow-up)
  • Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS-PL) (baseline and 12-week follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-06
Completion: 2028-04-30
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Collaborators: University of Southern California, University of California, Irvine, Columbia University, Mayo Clinic, University of California, San Francisco, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Tiffany Ho, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
Contact Information
Study Contact:
Tiffany Ho, Ph.D.
310-825-2961
tiffany.ho@psych.ucla.edu
Cheryl Sun, B.A.
cherylsun@psych.ucla.edu
Tiffany Ho, Ph.D.
310-825-0561
University of California, Los Angeles
Interventions
  • Behavioral: Trier Social Stress Test (TSST) — In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
Study Locations (1 sites)
University of California, Los Angeles, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: * All sexes and genders * All ethnicities * Ages 14-21 * Postpubertal (Tanner stage \> 3) * No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication) * Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram * The ability to provide assent, understand, and complete all study procedures * Caregiver consent (if applicable) Exclusion Criteria: * Primary mental health diagnosis other than a depressive disorder according to DSM-V * Any contraindications to MRI scanning, phlebotomy, or SSRI treatment * Stimulant usage * A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes * Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings * Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure * Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders * First-degree relative with current, past, or suspected mania or psychosis
Conditions Diabetes Mellitus, Type 2
Phase PHASE4
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fingolimod — 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
  • Drug: guideline-based treatment for DM — guideline-based treatment for DM

Primary Outcomes

  • The changes of glycosylated hemoglobin, compared with baseline (180 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-03-15
Completion: 2028-03-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: General Hospital of Shenyang Military Region
Principal Investigators:
  • HuiSheng Chen, Ph.D (PRINCIPAL_INVESTIGATOR) - The General Hospital of Northern Theater Command
Contact Information
Study Contact:
HuiSheng Chen
+8624897511
chszh@aliyun.com
Hui-Sheng Chen, Ph.D.
+86 13352452086
chszh@aliyun.com
Department of Neurology, General Hospital of Northern Theater Command
Interventions
  • Drug: Fingolimod — 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
  • Drug: guideline-based treatment for DM — guideline-based treatment for DM
Study Locations (1 sites)
Department of Neurology, General Hospital of Northern Theater Command, Shenyang, 110016 China
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-70 years old; 2. clinically diagnosed type 2 diabetes. 3. Glycosylated hemoglobin: 6.5% - 9.5%; 4. No drug treatment or only one oral hypoglycemic drug within 6 months; 5. Fasting blood glucose: \< 13.9mmol/l for those without medication, or \< 13.3mmol/l for those with medication; 6. if the antidiabetic drugs are taken, the dosage and the drug must be stable in the past 3 months. 7. Body mass index (BMI) ≤ 45 kg / m2; 8. Sign informed consent Exclusion Criteria: 1. patients with type 1 diabetes; 2. diabetic complications (ketoacidosis, hypertonic state, lactic acidosis). 3. Allergic to the study drug; 4. Abnormal liver and kidney function (transaminase greater than 2.5 times the upper limit of normal value; creatinine greater than 133umol / L); 5. Complicated with other serious organ diseases; 6. Recent disease history (within the past 6 months): myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or class III / IV heart failure; 7. Presence or history of mobitz type II second or third degree AV block or sick sinus syndrome, unless the patient has a pacemaker; 8. Baseline QT interval extension (male \> 450ms or female \> 460ms); 9. Treatment with class IA or class III antiarrhythmic drugs; 10. Patients with systemic infection (including but not limited to bacteria, fungi, viruses, etc.); 11. Participating in other clinical trials within 3 months; 12. Other circumstances that the investigator considers unsuitable for participating in this clinical study.
Conditions Obesity, Hypertension
Phase PHASE1, PHASE2
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Amlodipine — Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
  • Drug: Moxonidine — Moxonidine
  • Drug: Placebo — Placebo

Primary Outcomes

  • Endogenous glucose production (During two-step insulin clamp (six hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-05-20
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Contact Information
Study Contact:
Cynthia Laws, MS
615-421-1994
autonomicgroup@vumc.org
Vanderbilt University Medical Center
Alfredo Gamboa, MD
alfredo.gamboa@vumc.org
Vanderbilt University Medical Center
Italo Biaggioni, MD
Vanderbilt University Medical Center
Interventions
  • Drug: Amlodipine — Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
  • Drug: Moxonidine — Moxonidine
  • Drug: Placebo — Placebo
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Males and females of all races between 18 and 65 years of age * Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication. * Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2. * Able and willing to provide informed consent. Exclusion Criteria: * Pregnancy or breast feeding * Current smokers or history of heavy smoking (\>2 packs/day) * History of alcohol or drug abuse * Previous allergic reaction to study medications * Type I diabetes. * Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy * History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack * History or presence of immunological or hematological disorders * Impaired renal function * Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month) * Treatment with any investigational drug in the 1 month preceding the study * Inability to give, or withdraw, informed consent * Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol, inability to find IV access)
Conditions Dyslipidemias, Atherosclerosis, Diabetes...
Phase PHASE4
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Omega 3-Atorvastatin — Atmeg 2 capsules with 1 pack of Omethyl cutielet
  • Drug: Omega 3-Atorvastatin — Atmeg 2 capsules
  • Drug: Atorvastatin-Ezetimibe — ezetimibe/atorvastatin 10/20 mg

Primary Outcomes

  • Carotid intima media thickness (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-10-01
Completion: 2026-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Collaborators: Korea United Pharm. Inc.
Contact Information
Study Contact:
Soo Lim
+82-31-787-7035
limsoo@snu.ac.kr
Minji Sohn
rainbowmjs@naver.com
Soo Lim, MD, PHD
01097662706
limsoo@snu.ac.kr
SNUBH
Interventions
  • Drug: Omega 3-Atorvastatin — Atmeg 2 capsules with 1 pack of Omethyl cutielet
  • Drug: Omega 3-Atorvastatin — Atmeg 2 capsules
  • Drug: Atorvastatin-Ezetimibe — ezetimibe/atorvastatin 10/20 mg
Study Locations (1 sites)
SNUBH, Seongnam-si, Gyeonggi-do 13620 South Korea
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit * Male or female of 20 years or over * Mixed dyslipidemia under moderate-intensity statin: triglyceride ≥200 mg/dL, HDL-cholesterol ≤50 mg/dL, LDL-cholesterol ≥100 mg/dL * moderate-intensity statin: atorvastatin 10-20mg, rosuvastatin 5mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg, fluvastatin XL 80mg, fluvastatin 40mg bid, pitavastatin 2-4mg * Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm * Asymptomatic patients without history of angina, myocardial infarction, or cerebral infarction * Creatinine ≤1.8 mg/dL Exclusion Criteria: * Dyslipidemia which requires other therapy: triglyceride ≥500 mg/dL or LDL-cholesterol ≥190 mg/dL * Uncontrolled hypertension: SBP \>180 mmHg or DBP \>110 mmHg * Severe renal dysfunction: eGFR \<30 mL/min/1.73m2 * AST/ALT \>120/120 or chronic liver disease * Pregnant or childbearing woman who does not have enough contraception * Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months * Usage of dyslipidemia therapy other than statin
Conditions Type1diabetes, Type 2 Diabetes, Adiposit...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Diabetes registry for biomarker research Graz is a prospective cohort-study including subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity and dyslipidemia, aiming to collect data, blood and urine samples of all subjects on an annual basis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — In this registry no intervention is carried out

Primary Outcomes

  • Biomarker identification (Over entire period of registry (20 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-10-21
Completion: 2035-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Principal Investigators:
  • Harald Sourij, MD (PRINCIPAL_INVESTIGATOR) - Medical University of Graz
Contact Information
Study Contact:
Caren Sourij, MD
caren.sourij@medunigraz.at
Harald Sourij, MD
ha.sourij@medunigraz.at
Caren Sourij, MD
caren.sourij@medunigraz.at
Medical University of Graz
Interventions
  • Other: No intervention — In this registry no intervention is carried out
Study Locations (1 sites)
Medical University of Graz, Graz, 8010 Austria
Eligibility Criteria
Inclusion Criteria: * 18 - 99 years * Informed consent has to be given in written form * At least one of the following diseases: * Type 1 diabetes * Type 2 diabetes * Type 3 diabetes * Maturity onset diabetes of young (MODY) * Late onset diabetes of the adult (LADA) * Adipositas (BMI \> 30kg/m2) * Lipid metabolism disorder Exclusion Criteria: * No written informed consent * No willingness to participate in this registry
Conditions Solid Tumor, Gastrointestinal Cancer, Br...
Phase PHASE1, PHASE2
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This pilot feasibility study aims to set the foundation to investigate the applicability of QPOP drug selection followed by CURATE.AI-guided dose optimisation of the selected azacitidine combination therapy for solid tumours using CURATE.AI within the current clinical setting. QPOP will identify drug interactions towards optimal efficacy and cytotoxicity from the pre-specified drug pool based on ex vivo experimental data from the individual participant's tissue sample model. With these drug interactions, QPOP will identify the optimal drugs for the specific participant whose biopsy provided the cells for the ex vivo experimentation. Subsequently, CURATE.AI will be used to guide dosing for the selected combination therapy for that participant. Individualised CURATE.AI profiles will be generated based on each participant's response to a set of drug doses. Subsequently, the personalised CURATE.AI profile will be used to recommend the efficacy-driven dose. CURATE.AI will operate only within the safety range for each drug pre-specified for each participant. This pilot feasibility study will inform the investigators on the logistical and scientific feasibility of performing a large-scale randomised controlled trial (RCT) with the selected azacitidine combination therapy regimens and response markers. A secondary objective is to collect toxicity and efficacy data using established and exploratory response markers within and in-between cycles as exploratory outcomes.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: QPOP — QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
  • Device: CURATE.AI — CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment. The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant. The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months.
  • Drug: Azacitidine + docetaxel — Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8 Each chemotherapy cycle will be 21 days.
  • Drug: Azacitidine + paclitaxel — Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8 Each chemotherapy cycle will be 21 days.
  • Drug: Azacitidine + irinotecan — Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8. Each chemotherapy cycle will be 21 days.

Primary Outcomes

  • QPOP applicability: percentage of participants with successful application of QPOP drug selection. (up to 18 months)
  • CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile. (up to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-02-13
Completion: 2027-04-04
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University Hospital, Singapore
Collaborators: The N.1 Institute for Health (N.1), Cancer Science Institute of Singapore
Principal Investigators:
  • Wei Peng Yong (PRINCIPAL_INVESTIGATOR) - National University Hospital, Singapore
Contact Information
Study Contact:
Wei Peng Yong
6779 5555
Wei_Peng_Yong@nuhs.edu.sg
Wei Peng Yong
69082222
Wei_Peng_Yong@nuhs.edu.sg
National University Hospital
Wei Peng Yong
National University Hospital
Interventions
  • Device: QPOP — QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
  • Device: CURATE.AI — CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment. The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant. The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months.
  • Drug: Azacitidine + docetaxel — Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8 Each chemotherapy cycle will be 21 days.
  • Drug: Azacitidine + paclitaxel — Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8 Each chemotherapy cycle will be 21 days.
  • Drug: Azacitidine + irinotecan — Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8. Each chemotherapy cycle will be 21 days.
Study Locations (1 sites)
National University Hospital, Singapore, 119074 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Males and females ≥ 21 years of age. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 3. Patients must meet the following clinical laboratory criteria within 21 days of starting treatment: 1. Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 2. Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN of ≤ 5 ULN if involvement of the liver. 3. Calculated creatinine clearance ≥ 30 mL/min or creatinine \< 1.5 x ULN. 4. Diagnosed with breast or gastric cancer, where docetaxel, paclitaxel or irinotecan is indicated for palliative therapy. 5. Patients who have undergone QPOP drug screen (e.g. under QGAIN (2019/00924) or NGAIN trial (2021/00009) where the drug screen indicated potential benefit of combining azacitidine with taxane or irinotecan. 6. Patients must have raised response marker above upper limit of local laboratory normal (e.g. CEA and/or CA19-9, CA 15-3, CA 125, AFP, and methylation markers such as but not limited to DNMT). Exclusion Criteria: 1. Patients who are lactating or pregnant. 2. Patients with clinically significant hypersensitivity to one or more of the selected regimen's constituent drug(s) (e.g. patients with clinically significant hypersensitivity to irinotecan may not be enrolled on azacitidine + irinotecan, but may be allowed on azacitidine + paclitaxel or azacitidine + docetaxel). 3. Contraindication to any of the required concomitant drugs or supportive treatments. 4. Any clinically significant medical disease or psychiatric condition that, in the co-investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent. 5. Major surgery within 28 days prior to start of the treatment. 6. Active congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained. 7. Patients who previously underwent chemotherapy treatment with either docetaxel, paclitaxel and/or irinotecan may still be able to enrol into treatment with the same drug in combination with azacitidine provided they fulfil all other criteria and approval is sought by PI and Sponsor (e.g. patients previously treated with paclitaxel and are enroling for treatment with paclitaxel + azacitidine). 8. Patients with clinical suspicion or diagnosis of Gilbert's syndrome will not be allowed to enrol with azacitidine + irinotecan, but may be allowed to enrol for treatment with azacitidine + docetaxel or azacitidine + paclitaxel provided they fulfil all other criteria.
Conditions Depression, Anxiety
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

There is growing evidence for the effectiveness of internet-delivered cognitive behaviour therapy (ICBT) for post-secondary students with symptoms of depression and anxiety. In ICBT, clients review structured online content over several weeks to learn strategies and skills to manage their symptoms. Low treatment completion rates remain a concern for post-secondary students, so it is possible that existing treatment protocols do not offer enough flexibility for students' needs and preferences. This trial will examine students' preferences for different course options (fast-track, 5-week, and 8-week) and compare enrollment, adherence, and outcomes of students who pick each of the three options. In all three options, students will receive optional therapist support, in which the assigned therapist only contacts the student on weeks where the student sends the therapist a message. This trial will help inform the delivery of flexible treatment options for post-secondary students in a routine care setting.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Wellbeing Course for Students (Fast Track) — The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
  • Behavioral: Wellbeing Course for Students (5 weeks) — The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
  • Behavioral: Wellbeing Course (8 weeks) — The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.

Primary Outcomes

  • Patient Health Questionnaire 9-item (PHQ-9) (Baseline (screening), weeks 1-5 (Fast-Track and 5-week course), weeks 1-8 (8-week course), and week 16 (all course options))
  • Generalized Anxiety Disorder 7-item (GAD-7) (Baseline (screening), weeks 1-5 (Fast-Track and 5-week course), weeks 1-8 (8-week course), and week 16 (all course options))
  • Perceptions of Academic Functioning (PAF) (Baseline (screening), weeks 1-5 (Fast-Track and 5-week course), weeks 1-8 (8-week course), and week 16 (all course options))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-11-01
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Ministry of Health, Saskatchewan
Principal Investigators:
  • Vanessa Peynenburg, MA (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Marcie Nugent, MSW
3063372946
marcie.nugent@uregina.ca
Heather Hadjistavropoulos, PhD
3065855133
hadjista@uregina.ca
Marcie Nugent, MSW
3063373331
marcie.nugent@uregina.ca
Online Therapy Unit, University of Regina
Interventions
  • Behavioral: Wellbeing Course for Students (Fast Track) — The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
  • Behavioral: Wellbeing Course for Students (5 weeks) — The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
  • Behavioral: Wellbeing Course (8 weeks) — The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
Study Locations (1 sites)
Online Therapy Unit, University of Regina, Regina, Saskatchewan S4S 0A2 Canada
Eligibility Criteria
Inclusion Criteria: * registered as a student at a post-secondary institution in Saskatchewan; over the age of 18; endorse symptoms of depression (score of 5 or greater on the PHQ-9) and/or anxiety (score of 5 or greater on the GAD-7); and be able to access computers and the Internet and be comfortable using them Exclusion Criteria: * high risk of suicide or hospitalization for mental health in previous 12 months; unmanaged alcohol or drug use problems; severe psychiatric illness that is not managed (e.g. psychosis or mania); or receiving other psychological services more than twice per month
Conditions Hypertension, High Blood Pressure, Diabe...
Phase NA
Enrollment 425
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140/90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the "intervention arm" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: LINKED-HEARTS Program — The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

Primary Outcomes

  • Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2027-04-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 425 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Yvonne Commodore-Mensah, PhD, MSH, RN (PRINCIPAL_INVESTIGATOR) - JHU School Of Nursing
Contact Information
Study Contact:
Yvonne Commodore-Mensah, PhD, MSH
443-614-1519
ycommod1@jhu.edu
Andrew Robie, MD
Unity Health Care
Sarah Rubin
Johns Hopkins Community Physicians
Interventions
  • Behavioral: LINKED-HEARTS Program — The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
Study Locations (3 sites)
Unity Health Care, Washington D.C., District of Columbia 20019 United States
Johns Hopkins Community Physicians, Baltimore, Maryland 21205 United States
Choptank Community Health Systems, Denton, Maryland 21629 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age as of date of data extraction, 2. Self-identify as non-Hispanic white, non-Hispanic Black/African American and/or Hispanic, 3. Diagnosis of Hypertension (HTN) defined by International Classification of Diseases, Tenth code (ICD-10 code) and elevated systolic blood pressure (SBP) measure (≥140 mm Hg) on their most recent clinic visit. 4. Diagnosis of diabetes or chronic kidney disease (both defined by ICD-10 code), in addition to HTN 5. Receives primary medical care at one of the participating health systems 6. Have a Maryland and D.C. home address Exclusion Criteria: 1. Age \<18 years 2. Diagnosis of end-stage renal disease (ESRD) treated with dialysis 3. Serious medical condition which either limits life expectancy or requires active management (e.g., cancer) 4. Cognitive impairment or other condition preventing participation in the intervention 5. Planning to leave the practice or move out of the geographic area in 24 months 6. No longer consider the practice site their location for primary care 7. Unwillingness to provide informed consent
Conditions Fibromyalgia, Electroacupuncture, Acupun...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Fibromyalgia (FM) is a complex, multifactorial syndrome characterized by widespread chronic pain with hyperal- gesia and allodynia and a constellation of somatic and psychological manifestations, including fatigue, sleep dis- orders, depression, anxiety, gastrointestinal and cognitive disorders. FM is now recognized as one of the most common chronic pain conditions and its management remains a challenge for patients and healthcare profes- sionals. The fact that FM is associated with chronic pain without any obvious peripheral tissue damage has given rise to the concept of nociplastic pain with evidence of dysfunction in mono-aminergic neurotransmission, lead- ing to elevated levels of excitatory neurotransmitters and decreased levels of serotonin and norepinephrine in the spinal cord at the level of descending anti-nociceptive pathways. Additionally, dopamine dysregulation and altered activity of endogenous cerebral opioids have been observed in FM. Recent European guidelines on FM treatment emphasize that there should be a comprehensive assessment of patient's pain, function and psychosocial context. It is recognized that there are profound and fundamental problems associated with the pain assessment tools in common use, as most of these represent an attempt to reduce a multidimensional experience to a coarse unidimensional measure. Use of multiple tools for sub- jective and objective assessment of pain may reflect more accurately patient's pain experience. Furthermore, tracing a biologic pain marker in FM patients would facilitate both the initial assessment of pain and the re- sponse to treatment. Management of pain in FM patients should focus first on non-pharmacological modalities. Acupuncture therapy is an effective and safe treatment and exerts its analgesic effect through activation of pe- ripheral and central pain control systems with the release of β-endorphins, enkephalins, dynorphins, serotonin, norepinephrine, γ-aminobutyric acid or ATP. The aim of our study is to assess initially reported pain and evaluate the effectiveness of electroacupuncture (with or without diet modifications) on the "whole experience of pain" in FM patients in a multimodel assessment frame.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Electroacupuncture — Subjects will be administered electroacupuncture as described in the electroacupuncture group description
  • Dietary Supplement: Nutrition — Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
  • Dietary Supplement: Dietary supplement — Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description

Primary Outcomes

  • MOR - positive Bcells - baseline (Baseline)
  • MOR - positive Bcells - 6th session of electroacupuncture (End of 6th session of electroacupuncture- 3 weeks after baseline)
  • MOR - positive Bcells - 12th session of electroacupuncture (End of 12th session of electroacupuncture - 6 weeks after baseline)
  • MOR - positive Bcells - 6 months after the end of the 12th session (6 months after the end of 12th session of electroacupuncture)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-31
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Crete
Collaborators: University Hospital of Crete
Contact Information
Study Contact:
Vasileia Nyktari
+302810392994
vnyktari@gmaill.com
Papaioannou
+302810392994
Maria Skoula, Secretary
secrupgr@med.uoc.gr
University Hospital of Heraklion
Interventions
  • Other: Electroacupuncture — Subjects will be administered electroacupuncture as described in the electroacupuncture group description
  • Dietary Supplement: Nutrition — Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
  • Dietary Supplement: Dietary supplement — Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
Study Locations (1 sites)
University Hospital of Heraklion, Heraklion, 700 13 Greece
Eligibility Criteria
Inclusion Criteria: * Patient's consent * Age \>18 years old * Patients with diagnosed fibromyalgia from rheumatologists * Widespread pain more than 6 months * In case of drug therapy, it should be taken at least one month before the beginning of the session and remain stable till the end of the study Exclusion Criteria: * Deep depression * Biological agent use ( TNF inhibitors) * Heamatological diseases * Systemic Infections * pregnancy * electroacupuncture contraindications (epilepsy, pacemaker/ implantable cardioverter defibrillator (ICD)

Viral Mucosal Reprogramming

NCT05331170
Recruiting
Conditions Asthma, Allergic Rhinitis, Cat Allergy, ...
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Biological: Research Grade RG-RV — Exploration of the effects of RV inoculation on human airway mucosal programming in vivo

Primary Outcomes

  • ZEB-1 Expression (Immediate)
  • Type III Interferon (Immediate)
  • PD-L1 Expression (Immediate)
  • RV16 Viral Titer (48 hours after inoculation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-04-27
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Medical Branch, Galveston
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • William J. Calhoun, MD (PRINCIPAL_INVESTIGATOR) - University of Texas
Contact Information
Study Contact:
Lisa Sweeney, RN
409-747-5871
lanemeth@utmb.edu
Lisa Sweeney, RN
409-747-5871
lanemeth@utmb.edu
University of Texas Medical Branch
Cindy Mitchell, CCRC
409-772-5508
cimitche@utmb.edu
University of Texas Medical Branch
Interventions
  • Biological: Research Grade RG-RV — Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
Study Locations (1 sites)
University of Texas Medical Branch, Galveston, Texas 77555 United States
Eligibility Criteria
Inclusion Criteria: Healthy Normal Control Group 1. Subject must be able to understand and provide informed consent 2. Age: 18-60 inclusive 3. Sex: M or F 4. No history of asthma, COPD, rhinitis, or other clinically important respiratory disease 5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote. 6. No history of diabetes or cardiovascular disease 7. Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months. Allergic Rhinitis Group 1. Subject must be able to understand and provide informed consent 2. Age: 18-60 inclusive 3. Sex: M or F 4. No history of asthma, COPD, or other clinically important respiratory disease 5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote 6. No history of diabetes or cardiovascular disease 7. History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months 8. Seasonal or perennial nasal congestion or sneezing 9. Seasonal or perennial conjunctival infection or watering 10. No evidence of airway obstruction (FEV1:FVC ≥ lower limit of normal) 11. Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months. Allergic Asthma Group Inclusion Criteria 1. Subject must be able to understand and provide informed consent 2. Age: 18-60 inclusive 3. Sex: M or F 4. No history of COPD or other clinically important respiratory disease other than asthma 5. Non-smoker, or ex-smoker with \<10 pack years, at least 5 years remote 6. No history of diabetes or cardiovascular disease 7. History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months 1. Airway obstruction (FEV1: FVC \<0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months) 2. Requiring ICS for control of asthma for at least 30 days within the past 12 months 8. Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months. 9. Results of the CBC do not show clinically important abnormalities Exclusion Criteria: Healthy Group Normal Group 1. Inability or unwillingness of a participant to comply with study protocol 2. Currently taking inhaled corticosteroids, leukotriene modifier, or antihistamines for respiratory disease. 3. Neutralizing Ab to RV16 greater than or equal to 1:8 4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study. 5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV). 6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver). Allergic Rhinitis Group 1. Inability or unwillingness of a participant to comply with study protocol 2. Currently using inhaled steroids, or oral montelukast for respiratory disease 3. Neutralizing Ab to RV16 greater than or equal to 1:8 4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study. 5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) . 6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver). 7. Subjects who have received immunosuppressive treatment within the last 12 months 8. BMI is greater than 35 9. History of symptoms consistent with a viral URI within the past 21 days 10. Results of the CBC do not show clinically important abnormalities 11. Family history or medical history of liver disease or bleeding disorders 12. Have not received systemic corticosteroids for 3months prior to Screening 13. Antiplatelet agents other than aspirin 14. Subjects who have a positive COVID-19 test will be excluded for 8 weeks Allergic Asthma Group 1. Inability or unwillingness of a participant to comply with study protocol 2. Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs. 3. Neutralizing Ab to RV16 greater than or equal to 1:8 4. FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted 5. Recent (\<30 days) exacerbation of asthma requiring systemic corticosteroids 6. ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening. 7. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study. 8. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) . 9. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver). 10. Subjects who have received immunosuppressive treatment within the last 12 months 11. BMI is greater than 35 12. History of symptoms consistent with a viral URI within the past 21 days 13. Family history or medical history of liver disease or bleeding disorders 14. Have not received systemic corticosteroids for 3 months prior to Screening 15. Have an ACT score \>19 at the time of enrollment. 16. Antiplatelet agents other than aspirin 17. Subjects who have a positive COVID-19 test will be excluded for 8 weeks
Conditions Medication Refractory Epilepsy Patients ...
Phase NA
Enrollment 25
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neuropsychiatric disorders are a leading cause of disability worldwide with depressive disorders being one of the most disabling among them. Also, millions of patients do not respond to current medications or psychotherapy, which makes it critical to find an alternative therapy. Applying electrical stimulation at various brain targets has shown promise but there is a critical need to improve efficacy. Given inter- and intra-subject variabilities in neuropsychiatric disorders, this study aims to enable personalizing the stimulation therapy via i) tracking a patient's own symptoms based on their neural activity, and ii) a model of how their neural activity responds to stimulation therapy. The study will develop the modeling elements needed to realize a model-based personalized system for electrical brain stimulation to achieve this aim. The study will provide proof-of-concept demonstration in epilepsy patients who already have intracranial electroencephalography (iEEG) electrodes implanted for their standard clinical monitoring unrelated to this study, and who consent to being part of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.

Primary Outcomes

  • Decoded depression symptom ratings based on neural activity (5-10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-08
Completion: 2026-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: University of California, San Francisco, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Maryam M Shanechi, PhD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Maryam M Shanechi, PhD
213-740-1377
shanechi@usc.edu
HyeongChan Jo, PhD
hj_380@usc.edu
Maryam Shanechi, PhD
213-740-1377
shanechi@usc.edu
University of Southern California
Interventions
  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
Study Locations (2 sites)
University of Southern California, Los Angeles, California 90089 United States
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Patients being evaluated for surgical treatment of medication refractory epilepsy and brain tumors will be studied. ONLY patients with electrodes implanted based on clinical criteria to locate their seizure focus will be studied. Most patients are healthy adults, outside of their epilepsy and/or brain tumor. * Subjects \>= 18 are only included in this study. * All patients with the above conditions and with implanted electrode arrays who are willing to participate and able to cooperate and follow research instructions will be recruited. However, analysis of research recording data will focus on those subjects with an IQ \>= 80, with no impairments of reading, naming, or articulation (to minimize confounds such as abnormal language processing that may affect their self-reporting with the questionnaire), and with no cerebral pathology affecting the cortical regions from which recordings are made. Exclusion Criteria: * Subjects \< 18 years old will be excluded from this study due to the high concordance of developmental disorders (cognitive and language-related) in pediatric epilepsies. * There will be no involvement of special classes of subjects, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations. * Patients who are unable to give informed consent due to a brain disorder will be excluded from the study, as it is very likely that they would be unable to carry out the tasks demanded by the study.
Conditions Diabetes Mellitus, Type 1, Diabetes Mell...
Phase NA
Enrollment 128
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related distress, diabetes self-care, and social support and clinical outcomes -e.g., glycemic control. Focus group interviewing will be conducted to evaluate acceptability among intervention group participants.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Diabetes LIVE JustICE — Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
  • Other: Enhanced Education — See control group description above

Primary Outcomes

  • Demographics (baseline)
  • Potential Confounding Effects (week 1)
  • Potential Confounding Effects (week 2)
  • Potential Confounding Effects (week 3)
  • Potential Confounding Effects (week 4)
  • Potential Confounding Effects (week 5)
  • Potential Confounding Effects (week 6)
  • Metabolic Indicator (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-30
Completion: 2026-12-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Louise Reagan
Collaborators: American Diabetes Association
Principal Investigators:
  • Lousie Reagan, PhD (PRINCIPAL_INVESTIGATOR) - University of Connecticut
Contact Information
Study Contact:
Lousie Reagan, PhD
860-486-0593
louise.reagan@uconn.edu
Stephen Walsh, ScD
860-486-0544
stephen.walsh@uconn.edu
Louise A Reagan, PhD
18608745644
louise.reagan@uconn.edu
University of Connecticut
Interventions
  • Other: Diabetes LIVE JustICE — Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
  • Other: Enhanced Education — See control group description above
Study Locations (2 sites)
University of Connecticut, Storrs, Connecticut 06269 United States
University of Connecticut, Storrs Mansfield, Connecticut 06269-0001 United States
Eligibility Criteria
Inclusion Criteria: Individuals will be eligible to participate if they: 1. have Type 1 or 2 diabetes 2. are age 18 and older 3. can speak and understand English 4. have been released directly from one of five Connecticut prisons to supervised community housing or parole